Skip to main content
Premium Trial:

Request an Annual Quote

Cenix, ABI, TUD, ProNAi, Fisher Scientific

Premium
Cenix, ABI, TUD to Establish Facility Joining RNAi and Proteomics
 
Cenix BioScience, Applied Biosystems, and the Biotechnology Center of the Technische Universität Dresden said this week that they will jointly establish a new facility for proteomics profiling of RNAi and drug effects in human cells.
 
“The new facility will enable scientists from the three organizations to develop and deliver novel
research tools and methodologies that enable more detailed and probative analyses of the cellular functions of therapeutically relevant genes,” the partners said.
 
As part of a planned two-year effort to establish the facility, Cenix will contribute its expertise in RNAi screening and ABI will provide genetic and proteomic technologies and RNAi reagents from its Ambion unit while drawing on TUD’s academic training programs and biotechnology research.
Supporting the new facility, which will be located in Germany at the Dresden Bio-Innovation Centre, is a €1.2 million ($1.5 million) grant from the German government.
 

 
ProNAi Raises $6.65M in Bridge Funding
 
ProNAi Therapeutics has secured $6.65 million in bridge funding from several financing sources, the company said this week.
 
The Kalamazoo, Mich.-based startup uses DNA interference to develop drugs aimed at treating non-Hodgkin's lymphoma and prostate, breast, and colon cancers.
 
The company said it will use the funding to continue development of its lead drug candidate, PNT-100. ProNAi said it hopes to submit the compound to the FDA as an investigational new drug in mid-2007.
 
The current funding round includes $3.3 million that the company had previously announced from the Michigan Economic Development Corporation. Other sources for the new funding include Apjohn Ventures, Grand Angels, Amherst Fund, and Sigvion Ventures.
 
ProNAi has raised $11 million since its founding in 2004.
 

 
Fisher Posts Double-Digit Increase in Q3 Revenues, Profit
 
Fisher Scientific this week reported a 10.8 percent increase in third-quarter sales and a 62 percent spike in income.
 
For the quarter ended Sept. 30, Fisher posted net sales of $1.51 billion as compared to $1.36 billion for the same quarter in 2005.
 
Net income increased to $152 million from $93.5 million last year.
 
Sales of scientific products and services in the third quarter increased to $1.17 billion, a 9.9- percent increase over the prior-year period, Fisher said.
 
As of Sept. 30, Fisher held $279 million in cash and equivalents.
 
Fisher is awaiting approval from the European Commission, which it expects by Nov. 9, to finalize its merger with Thermo Electron.
 
For 2006, Fisher said it expects total sales growth, excluding the effects of foreign exchange, of approximately 10 percent, with organic growth in its core scientific research and healthcare markets of 8 percent.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.